Key facts
- This page summarizes Adele M. Gulfo's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Apr 2025, 17:36.
Adele M. Gulfo - 15 Apr 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)
- Reporting relationship
- Director
- Issuer ticker
- NAMS
- Reported as of
- 15 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Apr 2025, 17:36:52 UTC
- Prior SEC filing
- 01 Apr 2025
- Next SEC filing
- 20 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Louise Kooij by Power of Attorney from Adele Gulfo
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adele M. Gulfo filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 17 Apr 2025.
Change
- Previous filing in this sequence was filed on 01 Apr 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NAMS
transaction
Ordinary Shares
Award
- Transaction value
- Shares
- +10,860
- Change %
- Price
- Shares after
- 10,860
- Date
- 15 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NAMS
transaction
Derivative
Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +50,700
- Change %
- Price
- $0.000000
- Shares after
- 50,700
- Date
- 15 Apr 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 50,700
- Exercise price
- $16.06
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
Footnote F2
Each RSU was granted on April 15, 2025 for no consideration.
Footnote F3
33% of the shares underlying the option will vest on April 15, 2026, the one-year anniversay of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for two years, subject to the Reporting Person's continued service through each such date.